Castor Introduces Castor CoPilot, A Novel AI Solution for Clinical Trials

June 13, 2024 02:13 PM BST | By EIN Presswire
 Castor Introduces Castor CoPilot, A Novel AI Solution for Clinical Trials
Image source: EIN Presswire

Castor launches Castor CoPilot, an innovative human-in-the-loop AI tool designed to replace manual data re-entry and SDV processes in clinical trials.

NEW YORK, NEW YORK, UNITED STATES, June 13, 2024 /EINPresswire.com/ -- Castor, a leader in clinical trial technology solutions, today announced the launch of Castor CoPilot, an innovative human-in-the-loop AI tool designed to replace manual data re-entry and source data verification (SDV) processes in clinical trials. This cutting-edge solution is set to debut at the DIA Global Global Annual Meeting 2024 in San Diego, with a live demonstration by CEO Derk Arts on Innovation Theater #3 at 12.15pm on June 17th.

Castor CoPilot employs advanced AI to automate and streamline data collection traditionally performed manually, thereby reducing the time required for data entry by up to 70% and eliminating the need for source data verification. The capability integrates seamlessly into existing workflows, supports risk-based monitoring, and is capable of being deployed in ongoing studies with minimal disruption.

Advancements and Collaborations:

As part of its Practical AI roadmap, Castor has previously launched the AI Study Builder and now introduces Castor CoPilot as its second major AI capability. These developments reflect Castor's strategic use of technology to minimize manual work and enhance trial efficiency. Furthermore, Castor’s collaboration with Microsoft has been instrumental in leveraging cloud computing and AI technologies to support these innovations, ensuring scalability and security across its platform.

Impact on Clinical Research:

"The introduction of Castor CoPilot is a significant step forward in our mission to reduce repetitive, expensive and unfulfilling work in clinical trials that is burning out site staff" stated Dr. Derk Arts, CEO of Castor. "Our CoPilot is taking aim at the real problems in Clinical Research: lack of site staff and exploding site burden. A problem that will only get exacerbated by the hype around AI drug discovery."

Castor CoPilot, seeks to reduce high turnover rates among site staff and clinical research associates by reducing the repetitiveness of day to day tasks, leading to improved job satisfaction and retention within the field. Its deployment is expected to increase operational margins by reducing the need for extensive manual data handling.

Castor has announced it will open a waitlist for interested sponsors looking to reduce burden in, initially, real-world-evidence studies.

About Castor:
Castor is at the forefront of transforming clinical trials through practical applications of AI and innovative data solutions. Committed to advancing medical research, Castor leverages its technology to automate complex processes, prioritize patient safety, and comply with regulations. With a focus on AI development, including collaborations with major technology providers like Microsoft, Castor is dedicated to improving the clinical trial experience and outcomes.

Join the waitlist: https://www.castoredc.com/castor-copilot-sign-up/
Follow Castor on LinkedIn: http://www.linkedin.com/company/castoredc/

Laura McLoughlin
Castor
[email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next